146 related articles for article (PubMed ID: 8275587)
1. Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response.
Geiger T; Towbin H; Cosenti-Vargas A; Zingel O; Arnold J; Rordorf C; Glatt M; Vosbeck K
Clin Exp Rheumatol; 1993; 11(5):515-22. PubMed ID: 8275587
[TBL] [Abstract][Full Text] [Related]
2. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
3. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis.
Takagi N; Mihara M; Moriya Y; Nishimoto N; Yoshizaki K; Kishimoto T; Takeda Y; Ohsugi Y
Arthritis Rheum; 1998 Dec; 41(12):2117-21. PubMed ID: 9870868
[TBL] [Abstract][Full Text] [Related]
4. CGP 47969A: effect on collagen induced arthritis in DBA/1 mice.
Geiger T; Rordorf C; Cosenti-Vargas A; Ferrini PG; Widler L; Glatt M; Vosbeck K
J Rheumatol; 1994 Nov; 21(11):1992-7. PubMed ID: 7869300
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy.
Williams RO; Marinova-Mutafchieva L; Feldmann M; Maini RN
J Immunol; 2000 Dec; 165(12):7240-5. PubMed ID: 11120857
[TBL] [Abstract][Full Text] [Related]
6. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.
Joosten LA; Helsen MM; Saxne T; van De Loo FA; Heinegard D; van Den Berg WB
J Immunol; 1999 Nov; 163(9):5049-55. PubMed ID: 10528210
[TBL] [Abstract][Full Text] [Related]
7. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease.
Cook AD; Braine EL; Campbell IK; Rich MJ; Hamilton JA
Arthritis Res; 2001; 3(5):293-8. PubMed ID: 11549370
[TBL] [Abstract][Full Text] [Related]
8. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
[TBL] [Abstract][Full Text] [Related]
9. Epitope specificity of antibody response against human type II collagen in the mouse susceptible to collagen-induced arthritis and patients with rheumatoid arthritis.
Iribe H; Kabashima H; Ishii Y; Koga T
Clin Exp Immunol; 1988 Sep; 73(3):443-8. PubMed ID: 2463122
[TBL] [Abstract][Full Text] [Related]
10. Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis.
Nandakumar KS; Holmdahl R
J Immunol Methods; 2005 Sep; 304(1-2):126-36. PubMed ID: 16125192
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody.
Banerjee S; Wei BY; Hillman K; Luthra HS; David CS
J Immunol; 1988 Aug; 141(4):1150-4. PubMed ID: 3135321
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1 potentiates the development of collagen-induced arthritis in mice.
Killar LM; Dunn CJ
Clin Sci (Lond); 1989 May; 76(5):535-8. PubMed ID: 2785895
[TBL] [Abstract][Full Text] [Related]
13. Effect of a monoclonal antibody against interleukin-4 on collagen-induced arthritis in mice.
Yoshino S
Br J Pharmacol; 1998 Jan; 123(2):237-42. PubMed ID: 9489611
[TBL] [Abstract][Full Text] [Related]
14. In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice.
Hom JT; Bendele AM; Carlson DG
J Immunol; 1988 Aug; 141(3):834-41. PubMed ID: 3260913
[TBL] [Abstract][Full Text] [Related]
15. Active immunization against IL-23p19 improves experimental arthritis.
Ratsimandresy RA; Duvallet E; Assier E; Semerano L; Delavallée L; Bessis N; Zagury JF; Boissier MC
Vaccine; 2011 Nov; 29(50):9329-36. PubMed ID: 22008816
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of collagen-induced arthritis in DBA/1J mice by recombinant TSG-6, a tumor necrosis factor/interleukin-1-inducible protein.
Mindrescu C; Thorbecke GJ; Klein MJ; Vilcek J; Wisniewski HG
Arthritis Rheum; 2000 Dec; 43(12):2668-77. PubMed ID: 11145024
[TBL] [Abstract][Full Text] [Related]
17. Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies.
Malfait AM; Williams RO; Malik AS; Maini RN; Feldmann M
Arthritis Rheum; 2001 May; 44(5):1215-24. PubMed ID: 11352257
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of T-cell-mediated arthritis in mice by treatment with a monoclonal antibody against interleukin-4.
Yoshino S; Yoshino J
Cell Immunol; 1998 May; 185(2):153-7. PubMed ID: 9636693
[TBL] [Abstract][Full Text] [Related]
19. Role of interleukin 1 in antigen-induced exacerbations of murine arthritis.
van de Loo AA; Arntz OJ; Bakker AC; van Lent PL; Jacobs MJ; van den Berg WB
Am J Pathol; 1995 Jan; 146(1):239-49. PubMed ID: 7856731
[TBL] [Abstract][Full Text] [Related]
20. Arthritis in mice that are deficient in interleukin-1 receptor antagonist is dependent on genetic background.
Zhou F; He X; Iwakura Y; Horai R; Stuart JM
Arthritis Rheum; 2005 Dec; 52(12):3731-8. PubMed ID: 16320323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
